What is the offer price of Alopexx, Inc. IPO?

The offer price is $5.00 per share. Alopexx, Inc. is offering approximately 2.4M shares.

When is Alopexx, Inc. IPO expected to list?

Alopexx, Inc. begins trading on Jun 25, 2026 on the NASDAQ.

Which exchange will Alopexx, Inc. list on?

Alopexx, Inc. plans to list its common stock on the NASDAQ under the ticker symbol ALPX.

What is the size of Alopexx, Inc. IPO?

For Alopexx, Inc. IPO, implied market capitalization is around $38.41M.

How can I subscribe to Alopexx, Inc. IPO?

US IPOs are allocated through brokerage platforms that participate in the offering. You can check with your broker (e.g., Robinhood, SoFi, Fidelity, Charles Schwab, etc.) to see whether they offer access to this IPO. Shares can also be bought on the exchange after listing.

What is the current status of Alopexx, Inc. IPO?

As of now, the IPO status is "upcoming". This reflects whether the deal has been filed, priced, or listed.

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

Tools

IPO Calendar GMP Tracker Subscription Status Allotment Status

IPOs

All IPOs Live IPOs Upcoming IPOs Closed IPOs Listed IPOs

Resources

eBooks

Company

Home About Us Privacy Policy Terms of Service

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

Want to stay updated?Subscribe to our newsletter

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

Tools

IPO Calendar GMP Tracker Subscription Status Allotment Status

IPOs

All IPOs Live IPOs Upcoming IPOs Closed IPOs Listed IPOs

Resources

eBooks

Company

Home About Us Privacy Policy Terms of Service

About IPO Scanner

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Want to stay updated?Subscribe to our newsletter

Alopexx, Inc.

ALPXNASDAQ

upcoming

Issue Size

$12.00M

Price Range

$5.00

7.68M o/s · 2.4M offered

Listing Price

$5.00

Probable listing

Jun 25, 2026

Sector

Biotechnology

About

Alopexx, Inc.

To date over 75 separate pathogens have been found to express PNAG.

While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management’s assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections.

In a first-in-man trial, our vaccine candidate, AV0328, has been shown to be well tolerated with no serious adverse events observed.

Alopexx, Inc. Overview

Ticker, listing venue and issuer profile

TickerALPX

ExchangeNASDAQ

Statusupcoming

SectorBiotechnology

IndustryHealth Care

CurrencyUSD

CIK Code1880995

CUSIP--

ISINKYG633251239

Offer & Key Dates

Pricing terms and IPO milestones

Price Range$5.00

Offer Price$5.00

Listing Price--

Current Price$10.00

Shares Offered2.4M

Shares Outstanding7.68M

Offer Size$12.00M

Market Cap$38.41M

Filing Date--

Priced Date--

Listed DateJun 25, 2026

Valuation & Multiples

Key valuation ratios and metrics

P / E--

P / Book--

P / Sales--

EV / EBITDA--

EPS--

Revenue / Share (TTM)--

Revenue--

Net Income--

Financial Health

Balance sheet strength and liquidity

Total Debt$170.10K

Total Assets$142.00K

Cash--

Free Cash Flow--

Current Ratio0

Quick Ratio0

Debt / Equity--

CapEx--

Financial Highlights

Historical financial performance

SEC Filings

Official documents from SEC EDGAR

Form	Filing Date	Document
S-1/A	Feb 25, 2025	[Amend] General form for registration of securities under the Securities Act of 1933
S-1/A	Jan 8, 2025	[Amend] General form for registration of securities under the Securities Act of 1933
S-1/A	Sep 9, 2024	[Amend] General form for registration of securities under the Securities Act of 1933
S-1/A	Mar 14, 2024	[Amend] General form for registration of securities under the Securities Act of 1933
S-1/A	Dec 27, 2023	[Amend] General form for registration of securities under the Securities Act of 1933
FWP	Feb 1, 2023	Free Writing Prospectus
S-1/A	Feb 1, 2023	[Amend] General form for registration of securities under the Securities Act of 1933
S-1/A	Dec 15, 2022	[Amend] General form for registration of securities under the Securities Act of 1933
S-1/A	Nov 18, 2022	[Amend] General form for registration of securities under the Securities Act of 1933
S-1/A	Oct 7, 2022	[Amend] General form for registration of securities under the Securities Act of 1933

Company Info

Contact and headquarters details

Websitehttps://www.alopexx.com/

HeadquartersUnited States

Founded2006

Phone(617) 780-1598

Address186 Alewife Brook Pkwy #1068Cambridge, MA 02138United States

Leadership

Key executives and officers

Daniel R Vlock, MD

President, Chief Executive Officer and Director

Thomas T. Thomas

Chief Financial Officer

Gerald B. Pier, PhD

Chief Scientific Officer

William W. Chin, MD

Senior Strategic Advisor, Director

Christine de los Reyes, PharmD, MBA

Chief Business Officer, Chief Commercialization Officer

Peter J. Werth

Director

Alopexx, Inc. IPO - FAQs

Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). To date over 75 separate pathogens have been found to express PNAG. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management’s assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections. In a first-in-man trial, our vaccine candidate, AV0328, has been shown to be well tolerated with no serious adverse events observed.

Alopexx, Inc.

About

Alopexx, Inc. Overview

Offer & Key Dates

Valuation & Multiples

Financial Health

Financial Highlights

SEC Filings

Company Info

Leadership

Alopexx, Inc. IPO - FAQs

What is Alopexx, Inc. (ALPX) IPO?

What is the offer price of Alopexx, Inc. IPO?

When is Alopexx, Inc. IPO expected to list?

Which exchange will Alopexx, Inc. list on?

What is the size of Alopexx, Inc. IPO?

How can I subscribe to Alopexx, Inc. IPO?

What is the current status of Alopexx, Inc. IPO?